"Allowing switching between atopic dermatitis treatments"
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.05 05:00:52
가나다라
0
The latest guidelines from countries such as the 'Europe‧U.S.‧South Korea' mention need for switching treatments
Increased expectations after changes in the HIRA response due to evidence supporting switching between treatments
More options became available with the approval of biologics and JAK inhibitors to treat atopic dermatitis. However, limitations in switching treatments have been indicated to make effective treatments difficult.
Opinions have been suggested that the Korean government must follow the global trend as foreign countries do not limit switching between biologics and JAK inhibitors for treating moderate-to-severe atopic dermatitis.
▲Han Tae-young, Professor of Nowon Eulji Medical Center (Insurance Director at the Korean Atopic Dermatitis Association)
During a press conference hosted by Abbvie, titled 'Press conference for the latest Rinvoq value for atopic dermatitis,' on July 3rd, Professor Han Tae-young of Nowon Eulji Medical Center (Insurance Director at the Korean Atopic Dermatitis Association), emphasized th
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)